Patents Assigned to DENALI THERAPEUTICS, INC.
  • CRYSTALLINE FORMS OF (S)-5-BENZYL-N-(5-METHYL-4-OXO-2,3,4,5-TETRAHYDROPYRIDO [3,2-B][1,4]OXAZEPIN-3-YL)-4H-1,2,4-TRIAZOLE-3-CARBOXAMIDE
    Publication number: 20240391933
    Abstract: Described herein are crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, the process of preparing the forms, and pharmaceutical compositions methods of use thereof.
    Type: Application
    Filed: April 25, 2024
    Publication date: November 28, 2024
    Applicant: Denali Therapeutics Inc.
    Inventor: Anantha Sudhakar
  • Compounds, compositions and methods
    Patent number: 12139478
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: November 12, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney
  • Kinase inhibitors and uses thereof
    Patent number: 12129263
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: October 29, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R. H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE
    Publication number: 20240317776
    Abstract: Described herein are solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrido[3,4-f][1,4]oxazepine-9-carbonitrile, the process of preparing the forms, pharmaceutical compositions comprising same, and methods of use thereof.
    Type: Application
    Filed: February 20, 2024
    Publication date: September 26, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Brian M. Fox, Christopher R.H. Hale
  • Compounds, compositions and methods
    Patent number: 12091392
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: September 17, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Jianwen A. Feng, Maksim Osipov, Arun Thottumkara
  • METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20240271327
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: April 23, 2024
    Publication date: August 15, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20240271326
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: February 7, 2024
    Publication date: August 15, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Robert C. Wells, Joy Yu Zuchero, Ryan J. Watts
  • Crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-B][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide
    Patent number: 11999750
    Abstract: Described herein are crystalline forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4H-1,2,4-triazole-3-carboxamide, the process of preparing the forms, and pharmaceutical compositions methods of use thereof.
    Type: Grant
    Filed: January 11, 2023
    Date of Patent: June 4, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventor: Anantha Sudhakar
  • Compounds, Compositions and Methods
    Publication number: 20240150376
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: August 10, 2023
    Publication date: May 9, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Phillip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • FUSION PROTEINS COMPRISING SULFOGLUCOSAMINE SULFOHYDROLASE ENZYMES AND METHODS THEREOF
    Publication number: 20240150736
    Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.
    Type: Application
    Filed: January 12, 2024
    Publication date: May 9, 2024
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Tina GIESE, Gunasekaran KANNAN, Mihalis S. KARIOLIS, Cathal S. MAHON
  • ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOF
    Publication number: 20240148866
    Abstract: Certain embodiments provide a fusion protein comprising an iduronate 2-sulfatase (IDS) amino acid sequence, an IDS variant amino acid sequence, or a catalytically active fragment thereof; and an anti-transferrin receptor (TfR) antibody as described herein, as well as methods of use thereof.
    Type: Application
    Filed: February 11, 2022
    Publication date: May 9, 2024
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Annie ARGUELLO, Tina GIESE, Gunasekaran KANNAN, Mihalis S. KARIOLIS, Cathal S. MAHON, Junhua WANG
  • METHODS OF ENGINEERING TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20240141058
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: January 9, 2024
    Publication date: May 2, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Compounds, compositions and methods
    Patent number: 11958840
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: April 16, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
  • METHODS FOR TREATING AND MONITORING FRONTOTEMPORAL DEMENTIA
    Publication number: 20240069041
    Abstract: The present disclosure provides methods and materials for screening a compound or monitoring a subjects response to a compound or dosing regimen for treating frontotemporal dementia (FTD). Methods and materials for identifying and treating a subject having FTD are also provided.
    Type: Application
    Filed: October 13, 2021
    Publication date: February 29, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Giuseppe Astarita, Sarah L. Devos, Gilbert Di Paolo, Meng Fang, Fen Huang, Todd P. Logan, Matthew J. Simon
  • Methods of engineering transferrin receptor binding polypeptides
    Patent number: 11912778
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Grant
    Filed: August 15, 2022
    Date of Patent: February 27, 2024
    Assignee: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereof
    Patent number: 11884944
    Abstract: Provided herein are proteins, which are capable of being transported across the blood-brain barrier (BBB) and comprise sulfoglucosamine sulfohydrolase (SGSH) enzyme-Fc fusion polypeptides. Certain embodiments also provide methods of using such proteins to treat Sanfilippo syndrome A.
    Type: Grant
    Filed: June 30, 2022
    Date of Patent: January 30, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Tina Giese, Gunasekaran Kannan, Mihalis S. Kariolis, Cathal S. Mahon
  • ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20240024432
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, Fc dimers and fusion proteins comprising such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: September 8, 2023
    Publication date: January 25, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • SOLID FORMS OF 4-(3,3-DIFLUORO-2,2-DIMETHYL-PROPANOYL)-3,5-DIHYDRO-2H-PYRIDO[3,4-F][1,4]OXAZEPINE-9-CARBONITRILE
    Publication number: 20240025915
    Abstract: Described herein are solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2H-pyrido[3,4-f][1,4]oxazepine-9-carbonitrile, the process of preparing the forms, pharmaceutical compositions comprising same, and methods of use thereof.
    Type: Application
    Filed: July 24, 2023
    Publication date: January 25, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Brian M. Fox, Christopher R.H. Hale
  • ENGINEERED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20240018253
    Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.
    Type: Application
    Filed: September 11, 2023
    Publication date: January 18, 2024
    Applicant: Denali Therapeutics Inc.
    Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
  • Fusion proteins comprising enzyme replacement therapy enzymes
    Patent number: 11866742
    Abstract: Provided herein are fusion proteins that comprise an enzyme replacement therapy enzyme and an Fc region, as well as methods of using such proteins to treat a lysosomal storage disorder. Methods for transporting agents across the blood-brain barrier are also provided herein.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: January 9, 2024
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Anastasia Henry, Mihalis S. Kariolis, Cathal S. Mahon, Adam P. Silverman, Ankita Srivastava, Julie Ullman